Fenretinide-associated multilayered retinal hemorrhage in a patient with hairy cell leukemia.
Intravenous fenretinide (4-HPR), a cytotoxic retinoid, is being evaluated as part of a phase I clinical trial for patients with hematologic malignancies. In its orally administered form, it is also being evaluated for the treatment of various malignancies and geographic atrophy in subjects with the dry form of age-related macular degeneration. The authors report a case of acute large subretinal and intraretinal hemorrhage noted immediately after initiation of intravenous fenretinide therapy in a patient with hairy cell leukemia. This case highlights the importance of considering multilayered retinal hemorrhage as a possible side effect of fenretinide therapy, especially in patients with underlying hematologic abnormalities.
Doheny Retina Institute, Doheny Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, 1450 San Pablo Street, Los Angeles, CA 90033, USA.
Hani
H
Salehi-Had
Carmen A
CA
Puliafito
D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D017313:Fenretinide / Q000009:adverse effects*; D006801:Humans; D007262:Infusions, Intravenous; D007943:Leukemia, Hairy Cell / Q000188:drug therapy*; D008875:Middle Aged; D012166:Retinal Hemorrhage / Q000139:chemically induced* / Q000175:diagnosis; D041623:Tomography, Optical Coherence
D000970:Antineoplastic Agents; D017313:Fenretinide